Vanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012

Conference Call and Webcast to Follow

ROCKVILLE, Md., Jan. 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2011, on Tuesday, February 14, 2012, before the market opens.

The Company will host a conference call at 10:00 AM ET on Tuesday, February 14, 2012 during which Vanda management will discuss the financial results.  To participate in the conference call, please dial 866-271-0675 (domestic) or 617-213-8892 (international) and use passcode 76685033.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Tuesday, February 14, 2012, beginning at 12:00 PM ET and will be accessible until Tuesday, February 21, 2012, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The passcode number is 37381299.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
[email protected]

SOURCE Vanda Pharmaceuticals Inc.

Suggested Articles

Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, researchers said.

After posting positive data that showed it could help slow down the degenerative ALS disease, Amylyx has been given a $30 million boost.

Sumitomo is looking to the merged pipeline to help offset the anticipated impact of the arrival of generic competitors to bipolar drug Latuda.